論文・技術情報追加のお知らせ

1. Drug-induced gingival diseases: insights from the FDA Adverse Event Reporting System (FAERS) database analysis.

薬剤性歯肉疾患の新規リスク因子:FAERS分析と臨床への示唆

対象DB：FAERS

2. Unveiling the hidden risk of caspofungin: insights from three adverse event reporting systems and network pharmacology integration.

カスポファンギンの安全性評価:有害事象と分子メカニズムの探求

対象DB：FAERS,JADER

3. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Definity.

Definityの探索的安全性評価:既知と新規有害事象の統合分析

対象DB：FAERS

4. Contemporary local anaesthetic-associated adverse events and mortality: a pharmacovigilance analysis of a US reporting system.

局所麻酔薬の死亡リスク:変化する傾向とリドカインの課題

対象DB：FAERS

5. Ocular Safety Evaluation of Toplic and Systemic Antifungal Medications: A Multi-Source Pharmacovigilance and Genomic Study.

抗真菌薬の眼有害事象:全身薬と局所薬の比較・メカニズム洞察

対象DB：FAERS

6. A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system.

ペキシダルチニブ有害事象:TGCT治療の性差とリスク評価

対象DB：FAERS

7. Real-world safety profile of mitomycin: signal detection and time-to-onset analysis from FDA adverse event reporting system and VigiAccess databases.

ミトマイシンの安全性評価:全身性毒性と早期リスク識別

対象DB：FAERS

8. Revisiting the Association Between Beta-blockers and Psoriasis: Evidence from Real-World Data.

β遮断薬と乾癬のリスク:多角的評価による検証

対象DB：FAERS

9. Comprehensive Analysis of Gastrointestinal Injury Induced by Nonsteroidal Anti-Inflammatory Drugs Using Data from FDA Adverse Event Reporting System Database.

NSAIDsの消化器有害事象リスク比較とパターン解析

対象DB：FAERS

10. Real-World Safety of Vedolizumab in Inflammatory Bowel Disease: A Retrospective Cohort Study Supported by FAERS Signal Analysis.

ベドリズマブの安全性評価:コホートとFAERS解析

対象DB：FAERS

11. Causal Inference of Adverse Drug Events in Pulmonary Arterial Hypertension: A Pharmacovigilance Study.

PAH治療薬の有害事象因果関係解析と安全性評価

対象DB：FAERS

12. Adverse Events and Drug Interactions Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment: A Descriptive Study Across Australian, Canadian, and American Adverse Event Databases.

嚢胞性線維症治療薬ETIの有害事象と薬物相互作用解析

対象DB：CVAR,FAERS

13. Correlation between gabapentin and depression: A study from the NHANES and FAERS databases.

ガバペンチン使用と抑うつリスクの関連性解析

対象DB：FAERS

14. A real-world safety signal detection study of ondansetron based on FAERS reports from 2014 to 2024.

オンダンセトロンの有害事象信号解析と性差評価

対象DB：FAERS

15. Comparative Safety Analysis of Avastin and Bevacizumab Biosimilars Based on Food and Drug Administration Adverse Event Reporting System.

アバスチンとベバシズマブバイオシミラーの有害事象比較解析

対象DB：FAERS

16. Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks.

ナブパクリタキセルとパクリタキセルの安全性比較解析

対象DB：FAERS

17. In Silico Exploration of Therapeutics for GLP-1 Receptor Agonist-Induced Nausea and Their in Vivo Validation in Mice.

GLP-1受容体作動薬の悪心軽減と有効併用薬解析

対象DB：FAERS

18. Drug-induced pulmonary edema: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS).

薬剤性肺水腫のリスク評価と高危険薬分析

対象DB：FAERS

19. Drug-Related Candidiasis Risk Profiling: A Real-World Pharmacovigilance Study Leveraging the FDA Adverse Event Reporting System (FAERS).

薬剤性カンジダ症のリスク要因と死亡率解析

対象DB：FAERS

20. Post-marketing safety monitoring of RSV vaccines: A real-world study based on the Vaccine Adverse Event Reporting System (VAERS).

RSVワクチンの安全性信号解析と初期市場監視

対象DB：FAERS,VAERS

21. Sex-specific risk signals and onset patterns of drug-induced peripheral neuralgia: a 20-year pharmacovigilance analysis based on FAERS real-world dat.

薬剤誘発末梢神経障害の性差・新規リスク解析

対象DB：FAERS

22. Recognizing potential immune checkpoint inhibitor-associated optic neuritis: insights from the FDA adverse event reporting system.

免疫チェックポイント阻害剤関連視神経炎のFAERS解析

対象DB：FAERS

23. Drug-Induced Insulin Autoimmune Syndrome: A FAERS Database and Network Pharmacology Analysis.

薬剤性インスリン自己免疫症候群の薬剤・分子機序分析

対象DB：FAERS

24. Risk of genitourinary tract infections with SGLT-2 inhibitors in type 2 diabetes mellitus: A meta-analysis of randomised controlled trials and disproportionality analysis using FAERS.

SGLT-2阻害薬の性器真菌感染リスクと臨床特徴解析

対象DB：FAERS

25. Safety Profiles of Trofinetide in Pediatric Rett Syndrome Population: A Real-World Postmarketing Pharmacovigilance Analysis.

トロフィネタイド使用の小児レット症候群安全性解析

対象DB：FAERS

26. Association Between Anticholinergic Drug Use and Febrile Neutropenia Induced by Anticancer Chemotherapy: Analysis of the Japanese Adverse Drug Event Report Database.

抗コリン薬使用と化学療法誘発発熱性好中球減少症の関連

対象DB：JADER

27. Safety Considerations for Natural Products with Adaptogenic and Immunomodulating Activities.

適応・免疫調整自然製品の安全性を包括的に評価

対象DB：VigiBase

28. Safety of Delayed Operation for Small Bowel Obstruction: Nationwide Real-World Data Analysis.

小腸閉塞の保存的治療は3日以上で切除リスク増加

対象DB：DPC

29. Impact of coronavirus disease 2019 on the clinical outcomes of acute pancreatitis: a nationwide observational study in Japan.

COVID-19併存で急性膵炎の重症化リスクが増加

対象DB：DPC

30. Association between body mass index and the prognosis of community-acquired pneumonia in patients with nontuberculous mycobacterial pulmonary disease: a retrospective cohort study using a nationwide inpatient database.

低BMIとNTM-PD患者の肺炎予後の関連を解析

対象DB：DPC

31. Independent association of depressed mood and high suicide risk as assessed by the patient safety screener-3 (PSS-3) with prolonged hospitalization: A single-center cross-sectional study.

PSS-3日本版で抑うつ・自殺リスクと入院期間を分析

対象DB：DPC

32. Regional variation in overweight and associations with regional profiles using a Japanese national open-source database.

地域経済特性が影響、日本の肥満地域差を分析

対象DB：NDB

33. Geographic distribution and trends of small-area burn claims in Japan: An analysis using NDB open data from 2014 to 2021.

日本の小範囲火傷、地域差と年次減少を分析

対象DB：NDB

34. Hypoglycemia-Related Hospitalization in Adults with Type 2 Diabetes Receiving Insulin in Japan: Real-World Analysis Using the Medical Data Vision Database.

日本T2D患者、基礎・追加開始で低血糖入院率増加

対象DB：MDV

35. Development and validation of a postpartum cardiovascular disease risk prediction model in women incorporating reproductive and pregnancy-related predictors.

妊娠因子追加でCVD予測改善、臨床的有用性向上

対象DB：CPRD

36. Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure.

NT-proBNP高値患者でSGLT2i・MRA早期導入の有益性

対象DB：CPRD

37. Estimating inequality in alcohol-related liver disease burden in the UK, 2009 to 2020: a population-based study using routinely collected data.

英国におけるARLD負担増加と健康格差の解明

対象DB：CPRD

38. Sodium-glucose cotransporter-2 inhibitors and the risk of all-cause mortality: a population-based cohort study using the UK Clinical Practice Research Datalink.

SGLT-2is、早期糖尿病で死亡率低下を示唆

対象DB：CPRD

39. Applicability of the electronic frailty index in younger and older adults in England: a population-based cohort study.

若年成人でのeFI評価、有効性と高リスク群の特定

対象DB：CPRD

40. Awareness and management of stage 3 chronic kidney disease among primary care practitioners in Italy: a nation-wide observational study.

イタリアGPのCKD管理実態、早期診断改善を提言

対象DB：THIN

41. Oral adverse event reporting in smoking cessation trials using non-combustible nicotine products: A quality assessment.

NCNP試験の口腔有害事象報告、基準改善を提案

対象DB：KAERS

42. Incidence and risk of cancer emergence among patients post-kidney transplantation in Japan.

腎移植後のがんリスク傾向、初の大規模長期解析

対象DB：DeSC